Calidi Biotherapeutics Announces Upcoming Presentations at the 2024 ASCO Annual Meeting
Join Calidi Biotherapeutics’ Exclusive Live Investor Webinar and Q&A Session on April 24
SAN DIEGO--(BUSINESS WIRE)--Calidi Biotherapeutics, Inc. (NYSE American: CLDI or “Calidi”), a clinical-stage biotechnology company developing a new generation of targeted immunotherapies, today announced the closing of its previously announced public offering of 15,197,500 shares of common stock (or pre-funded warrants in lieu thereof) and accompanying Series A Common Warrants, Series B Unit Warrants, with each unit consisting of one share of common stock and a Series B-1 Common Warrant and Series C Unit Warrants, with each unit consisting of one share of common stock and a Series C-1 Common Warrant at an effective combined price of $0.40 per share and common warrants for aggregate gross proceeds of approximately $6.1 million, before deducting placement agent fees and other offering expenses. The common warrants will have an exercise price of $0.60 per share, and the Series A Common Warrants, Series B Unit Warrant and Series C Unit Warrant will be exercisable immediately. The common warrants will expire in five years (with respect to the Series A Common Warrant, the Series B-1, Warrant and the Series C-1 Common Warrant), twelve months (with respect to the Series B common warrants) and four months (with respect to the Series C common warrants) from the issuance date.
Calidi Reports Fourth Quarter and Full-Year 2023 Operating and Financial Results
Calidi Biotherapeutics and City of Hope Announce Funding from CIRM
Calidi Biotherapeutics to Highlight Novel Systemic Enveloped Oncolytic Virotherapy Platform Designed to Target All Tumor Sites at Upcoming Conference
Calidi Biotherapeutics Announces Presentation of Clinical Study for NeuroNova
Calidi Biotherapeutics Announces Appointment of Pharmaceutical Industry Veteran David LaPré to its Board of Directors
Calidi Biotherapeutics Reports Third Quarter 2023 Financial Results
Calidi Biotherapeutics (NYSEAM: CLDI) Presents Data on CLD-201 Demonstrating Inhibition of Tumor Growth and Induction of Robust Anti-Tumor Immunity at the Society for Immunotherapy of Cancer’s 38th Annual Meeting (SITC 2023)